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AbstrAct:
Class  III  β-tubulin  (β3)  is  associated  with  tumor  aggressiveness,  resistance  to 
therapy, and patient relapse. To elucidate its action, we tested β3’s effect on cell 
migration. Expression of β3 in HeLa and MCF-7 did not alter the intrinsic rate of cell 
migration, but it prevented the inhibition of migration by low, nontoxic concentrations 
of paclitaxel. The effects on cell motility were confirmed in CHO cells with tetracycline 
regulated expression of β3. Cell migration and microtubule dynamics were inhibited 
by  similar  concentrations  of  paclitaxel,  but  required  a  5-10  fold  higher  drug 
concentration when β3 was expressed. The directionality of migration was normal 
in  paclitaxel,  but  cells  spent  more  time  in  a  “paused”  state  during  which  there 
was no net movement. These studies support a model in which paclitaxel inhibits 
cell  migration  by  suppressing  microtubule  dynamics  and  β3-tubulin  counteracts 
paclitaxel action by maintaining microtubule dynamic activity. The results provide 
a  potential  explanation  for  the  resistance  to  therapy  of  β3-expressing  tumors.
INtrODUctION
Microtubules form an important cytoskeletal 
network involved in cell shape, vesicle transport, cell 
motility, chromosome segregation, and cell division. 
Cellular microtubules are composed of αβ-tubulin 
heterodimers that assemble into linear protofilaments that 
associate laterally to form hollow, tube-like structures. 
The αβ heterodimers are added in a polarized fashion 
resulting  in  asymmetric  filaments  whose  fast  growing 
plus-ends are oriented towards the cell periphery while 
their slow growing minus-ends remain embedded in the 
centrosome near the cell center. Both α- and β-tubulin are 
encoded by multiple genes that are expressed in a tissue 
specific manner. In the case of β-tubulin, there are at least 
7 vertebrate genes that produce distinct isotypes: β1, β2, 
β3, β4a, β4b, β5, and β6. The β1, β4b, and β5 isotypes are 
found in most mammalian tissues, whereas β2, β3, and 
β4a are predominantly found in brain, and β6 is restricted 
to platelets and megakaryocytes [1, 2].
The functional consequences of expressing different 
tubulin genes have long been a subject of speculation [3]. 
Studies in cultured mammalian cells showed that cellular 
microtubules incorporate all available β-tubulin isotypes 
including ectopic and chimeric proteins with little or no 
change to the microtubule network [4-7]. On the other 
hand, studies in transgenic mice revealed an important 
role for β6  in  platelet  function  [8].  In  our  laboratory 
we recently used tetracycline regulated expression to 
examine the effects of ectopic β-tubulin cDNAs on cell 
behavior. Our studies have shown that overexpression of 
β1, β2, or β4b has no obvious effects on the transfected 
cells [9], and that β4a overexpression has only subtle 
effects on microtubule assembly and drug sensitivity [10]. 
In contrast, overexpression of the more divergent β5 and 
β6 isotypes produces dramatic effects on cell division, 
microtubule assembly, and cellular responses to drugs 
that target the microtubule cytoskeleton [11, 12].
The  β3  isotype  falls  between  these  extremes.  Its 
expression was reported to be increased in cell lines 
selected for resistance to paclitaxel [13, 14]. We confirmed 
its participation in paclitaxel resistance but showed that it 
could only confer very weak resistance and that it acted 
by reducing microtubule assembly [15]. Although β3 is Oncotarget 2011; 2:  368 - 377 369 www.impactjournals.com/oncotarget
normally restricted to neuronal and Sertoli cells, it has 
been found to be inappropriately expressed in tumor cells 
from diverse tissues and its presence appears to correlate 
with tumor aggressiveness and resistance to therapy [16, 
17]. As a measure of tumor cell aggressiveness, we tested 
the effects of β3 expression on the ability of paclitaxel to 
inhibit cell migration.
rEsULts
Neuron specific β3-tubulin is expressed in non-
neuronal cancer cell lines
Cell migration is a complex process that involves 
the microfilament and microtubule cytoskeletal systems 
[18, 19]. We recently showed that concentrations of 
microtubule inhibitors that are too low to affect cell division 
are  nevertheless  efficient  at  suppressing  microtubule 
dynamics and inhibiting cell motility [20]. Because β3-
tubulin has been reported to inhibit paclitaxel’s ability to 
suppress microtubule dynamics [21], we reasoned that β3 
expression in tumor cells might affect the ability of drugs 
like paclitaxel to inhibit cell motility. This in turn could 
potentially account, at least in part, for the observation 
that β3 expressing cells tend to be more aggressive and 
less susceptible to therapy with microtubule targeted 
drugs [16, 17].
To test this hypothesis, we screened several human 
tumor cell lines for their expression of β3-tubulin using 
both immunofluorescence and western blot analysis with 
an antibody specific for the β3 isoform. As a control, we 
used CHO cells that were previously shown to express 
β1, β4b, and β5 tubulin, but not β3 [22, 23]. As shown 
in Figure 1A, CHO cells (lane 1) failed to react with the 
antibody; but MCF7 (lane 2), HeLa (lanfe 3), and DU145 
(lane 4) cells, derived from human breast, cervical, and 
prostate tumors respectively, showed the presence of 
varying amounts of β3. Immunofluorescence microscopy 
(Figure 1B) confirmed the presence of β3-tubulin in the 
microtubules and further indicated that the staining varied 
greatly on a cell-to-cell basis. For example, we estimated 
that only 25% of the cells in the MCF7 cell population were 
positive for β3; whereas HeLa was 40% positive. Only the 
DU145 cells appeared mostly uniform for β3 production, 
but even in that cell line, there were some negative 
cells (arrows, Figure 1B). We also examined K562 and 
KB3 cells but found no evidence for β3 production by 
either  western  blot  analysis  or  by  immunofluorescence 
microscopy (data not shown). The results confirmed the 
presence of β3-tubulin in some, but not all, human tumor 
cell lines.
Cells that produce β3-tubulin resist the inhibitory 
effects of paclitaxel on cell migration
We used the heterogeneity of β3 expression in MCF7 
and HeLa cell lines as an advantage in order to assess the 
effects of this isotype on cell motility. Cells were grown 
on glass coverslips to about 85% confluence, a scratch was 
made in the monolayer, and the movement of cells into the 
wound was monitored by time lapse microscopy in the 
presence and absence of paclitaxel using a concentration 
that was one fifth of the cytotoxic IC50 value. Previous 
studies indicated that this concentration of drug would be 
effective at suppressing microtubule dynamics without 
affecting mitosis [24]. We predicted that in the presence of 
Figure 1: β3-Tubulin production in human cancer cell 
lines. (A) CHO (lane 1), MCF7 (lane 2), HeLa (lane 3), and 
DU145 (lane 4) cells were lysed and analyzed on western blots 
with antibodies to β3-tubulin and actin. (B) The indicated cell 
lines were stained with antibodies specific for α-tubulin and β3-
tubulin. Note the heterogeneity of the cells with respect to β3-
tubulin staining. Arrows for DU145 indicate the rare presence of 
cells that are β3 negative. Bar, 50 μm.Oncotarget 2011; 2:  368 - 377 370 www.impactjournals.com/oncotarget
drug, the migration of cells lacking β3 would be inhibited, 
but  β3-producing cells would continue to migrate and 
become concentrated at the edge of the wound. Because 
MCF7 cells migrate much more slowly than HeLa (5 versus 
22 µm/h), cells were fixed and stained for fluorescence 
microscopy at different time points (7 h for HeLa and 24 
h for MCF7) that corresponded to an approximate 30% 
closing of the wound. As anticipated, the β3-producing 
cells in both cell lines became enriched at the edge of 
the wound (Supplementary Figure 1A). To quantify the 
results, β3 positive and negative cells at the edge of the 
wound were counted in 20 microscopic fields chosen at 
random in each of 3 independent experiments. The data 
confirmed that there was an increased percentage of β3-
producing cells at the leading edge of the wound when 
paclitaxel was present (Supplementary Figure 1B) and 
indicated that β3 expression could be playing a significant 
role in the inability of microtubule targeted drugs to halt 
the migration of aggressive tumor cells.
Resistance to paclitaxel inhibition of motility is 
due to β3-tubulin expression
Although the production of β3-tubulin appeared 
to correlate with the insensitivity of cell migration to 
paclitaxel suppression, it did not establish a cause and 
effect relationship. Human tumor cell lines are notoriously 
heterogeneous and the cells frequently differ by multiple 
genetic  changes  that  could  influence  their  response  to 
paclitaxel treatment. Also, the cells were not uniform in 
their level of β3 production (see Figure 1B). Thus, cells 
with low production that might be sufficient to provide 
resistance could potentially be scored as β3-negative and 
thereby complicate the quantification of experiments such 
as those shown in Supplementary Figure 1. To eliminate 
these ambiguities, we turned to HAβ3-5, a cloned CHO cell 
line, created by transfection with HA-tagged β3-tubulin 
under the control of a tetracycline regulated promoter, that 
exhibits homogenous expression of the β3 isotype when 
the cells are grown in the absence of the antibiotic [15]. 
The parental CHO cells used to generate this cell line were 
shown to have no detectable expression of β3 by antibody 
binding (Figure 1A), 2D gel analysis [23], or sequencing 
of expressed cDNAs for β-tubulin [22]. By combining 
HAβ3-5 with wild-type cells, we created a wound healing 
experiment similar to that shown in Supplementary 
Figure 1A but with cells that were more clearly positive 
Figure 2:  Paclitaxel inhibition of cell migration. (A) A mixed culture of wild-type CHO cells and HAβ3-5 cells was scratched to 
make a wound and the cells were allowed to migrate for 24 h in the absence or presence of 10 nM paclitaxel. The cells were then stained 
for α-tubulin (red), HAβ3-tubulin (green), and DNA (blue). Arrows indicate the direction of movement. Bar, 50 µm. (B) Cells at the edge of 
the wound were scored for the presence or absence of HAβ3 expression and the percentage of HAβ3 containing cells was calculated from 
20 random fields each containing approximately 20 cells along the leading edge. The experiment was repeated 3 times. (C) In a separate 
experiment, a pure culture was used to measure the rate of HAβ3-5 cell migration into a scratch wound with and without 10 nM paclitaxel 
in the presence (open bar) and absence (solid bar) of tetracycline. (D) A transwell assay was used to measure the migration of cells from 
the upper to the lower chamber over a 6 h period at various paclitaxel concentrations. The graph was generated by defining the number of 
cells that migrated to the lower chamber at 0 nM paclitaxel as 100% and expressing the data for the other concentrations relative to the zero 
control. Error bars, SD. *p < 0.05 relative to the WT control was considered significant.Oncotarget 2011; 2:  368 - 377 371 www.impactjournals.com/oncotarget
or negative for β3 production. For inhibition we used 10 
nM paclitaxel, a concentration that is 1/5th of the IC50 for 
inhibition of cell division in CHO cells [24]. The results 
showed that HAβ3-containing cells (green cells, Figure 
2A) were relatively insensitive to the inhibitory effects of 
paclitaxel on cell migration and accumulated at the leading 
edge of the wound where they made up 95% of the cells 
versus only 50% of cells that migrated to the edge in the 
absence of drug (Figure 2B). As a further demonstration 
that β3 was the factor that mitigated the inhibitory effects 
of paclitaxel on cell migration, we directly measured the 
rates of migration of HAβ3-5 cells in the presence and 
absence of 10 nM paclitaxel under conditions in which 
HAβ3 was expressed or not expressed. The results showed 
that there was a significant paclitaxel-induced decrease in 
cell migration when the cells were tested in the presence 
of tetracycline (no HAβ3 expression; open bars in Figure 
2C), but the decrease in migration did not occur when 
the cells were tested in the absence of tetracycline (with 
HAβ3 expression; solid bars in Figure 2C).
β3-Tubulin’s ability to block paclitaxel inhibition of 
cell movement was also tested using a transwell migration 
assay in which wild-type or HAβ3-5 cells were plated 
on top of the membrane in the presence or absence of 
paclitaxel. After 6 h the membrane was fixed and stained 
with DAPI, and the cells that migrated to the bottom of 
the membrane were counted. It was observed that 10 nM 
paclitaxel effectively inhibited the migration of wild-
type cells though the pores of the transwell membrane; 
but the migration of HAβ3-5 was not inhibited at this 
concentration (Figure 2D). At the toxic concentration 
of 50 nM paclitaxel, on the other hand, the migration 
of both cell lines was similarly inhibited. Thus, by two 
independent assays, β3-tubulin expression was able to 
counteract the inhibitory effects of 10 nM paclitaxel on 
cell migration.
Paclitaxel inhibition of cell migration is mediated 
by suppression of microtubule dynamics
We previously reported that low nontoxic 
concentrations of vinblastine, colcemid, and other 
microtubule disrupting drugs effectively suppressed 
microtubule dynamics and inhibited cell migration [20]. 
To determine whether the microtubule stabilizing drug 
paclitaxel also suppresses dynamics at low subtoxic 
concentrations, we generated microtubule life history 
plots showing time-dependent changes of microtubule 
length in the presence and absence of paclitaxel (Figure 
3). In the absence of drug, microtubule plus ends in wild-
type CHO cells exhibited frequent episodes of growth and 
shortening interspersed with periods of pause in which 
there was no significant change in length (Figure 3A). The 
addition of 10 nM paclitaxel (Figure 3B), a concentration 
that effectively inhibited cell migration but not cell 
division, caused a pronounced suppression of microtubule 
plus end excursions that was similar to the suppression 
caused by 50 nM drug (Figure 3C), the IC50 for inhibition 
of cell division [24]. Thus, paclitaxel, like vinblastine and 
colcemid, was able to suppress microtubule dynamics at 
low, subtoxic concentrations.
Figure  3:    Paclitaxel  suppression  of  microtubule 
dynamics. Wild-type and HAβ3-5 cells were transfected with 
EGFP-MAP4 and microtubules were imaged every 5 s in the 
presence of the indicated concentrations of paclitaxel (Ptx). 
Microtubule lengths from an arbitrary internal reference point 
were plotted against time to describe the growth and shortening 
of the microtubule plus end. Each line represents a separate 
microtubule. Note that the position of the line on the y-axis is 
arbitrary and does not represent the actual total length of the 
microtubule.
Figure  4:  Effect  of  β3-tubulin  expression  on 
microtubule dynamics and cell migration. Wild-type 
CHO cells (WT, circles) and HAβ3-5 cells (squares) were 
treated with varying concentrations of paclitaxel and the 
effects of the drug on microtubule dynamicity (solid symbols) 
and cell migration (open symbols) were measured. Note the 
relative resistance of both microtubule dynamics and cell 
migration to the inhibitory effects of paclitaxel in HAβ3-5 
cells.Oncotarget 2011; 2:  368 - 377 372 www.impactjournals.com/oncotarget
As previously reported [21], microtubules in HAβ3-
5 cells were also dynamic in the absence of drug (Figure 
3D); but unlike wild-type cells, the dynamics were not 
suppressed by 10 nM paclitaxel (Figure 3E). Instead, a 
much higher drug concentration (50 nM) was needed to 
cause suppression (Figure 3F). Drug-induced changes in 
the various parameters that describe dynamic instability 
such as growth and shortening rates are summarized 
in Supplementary Tables 1 and 2 for both of these 
cell lines. The ability of drugs that promote or inhibit 
microtubule assembly to decrease cell migration at the 
low concentrations that suppress microtubule dynamics 
supports the conclusion that dynamic microtubules are 
needed for cell movement. This conclusion is further 
supported by the observation that β3-tubulin prevented 
the suppression of both microtubule dynamics and cell 
migration that is normally caused by treatment with 10 
nM paclitaxel.
To further illustrate the relationship between 
microtubule dynamics and cell movement, we compared 
the rate of cell migration with dynamicity, a parameter 
used to characterize the extent of dynamic behavior 
[25], at several additional paclitaxel concentrations and 
plotted the results in Figure 4. A close correlation was 
found between paclitaxel suppression of dynamicity and 
inhibition of cell migration for both the wild-type and 
HAβ3-5 cells. Moreover, the drug concentration needed 
to inhibit both processes in HAβ3-5 was approximately 
10-fold higher than in the wild-type cells. 
Paclitaxel  increases  pauses  between  cell 
movements
To determine whether paclitaxel inhibited the rate 
of cell movement or simply altered the directionality of 
movement into the wound, we tracked individual cells 
every 15 min as they moved into a scratch wound and the 
results are summarized in Figure 5. In the absence of drug, 
wild-type and HAβ3-5 cells moved predominantly in the 
direction of the wound with relatively few excursions 
in other directions (Figure 5A). The addition of 10 nM 
paclitaxel did not alter the directionality of movement, 
but the progress of the wild-type cells in the direction of 
Figure 5: Paclitaxel effects on cell movement. Wild-type and HAβ3-5 cells migrating into a wound in the presence and absence of 
paclitaxel were tracked for 5 h by marking the X and Y positions of the nucleus relative to a fixed internal reference point at 15 min intervals 
(open circles). For cases when the cell was paused (no movement) during one 15 min interval, the position is marked with a closed circle. 
When there was no movement during two 15 min intervals, the position is marked with an asterisk. Note that directionality didn’t change, 
but the frequency of pauses greatly increased at inhibitory concentrations of paclitaxel.Oncotarget 2011; 2:  368 - 377 373 www.impactjournals.com/oncotarget
the wound was clearly inhibited (Figure 5B). Some of this 
inhibition was due to a smaller average distance moved 
during each 15 min interval reflecting a slower velocity of 
movement; but even more strikingly, there was an increased 
frequency of pauses in which the cells failed to move at all 
during one (solid circles) and sometimes two (asterisks) 
15 min intervals. There was little further inhibition of 
cell movement when the paclitaxel concentration was 
increased to 50 nM (Figure 5C). Similar behavior was 
observed for cell line HAβ3-5, but inhibition of migration 
required the higher 50 nM drug concentration (Figure 5 
D-F). The average velocities and pause frequencies for 
each cell line with increasing concentrations of paclitaxel 
are summarized in Figure 6. Paclitaxel caused relatively 
small decreases in the velocity of cell movement (dark 
bars, averaged only during the intervals the cells actually 
moved), but caused larger decreases in the rate of cell 
migration (light bars, calculated as ½ of the rate of wound 
closure). The difference between these two calculations 
could be explained by the large drug-induced increase in 
pauses during which the cells did not exhibit appreciable 
movement (shaded bars). These observations led us to 
conclude that paclitaxel acts primarily to prevent cell 
movement, and that it has quantitatively smaller effects 
on the directionality or velocity of cells in motion.
DIscUssION
Drugs that target mitosis have proven to be very 
effective agents for treating cancer. Most of these drugs 
bind directly to tubulin to either inhibit or promote 
microtubule assembly. The antitumor effects of these 
agents are usually attributed to direct killing of the tumor 
cells by activation of a mitotic checkpoint followed by 
apoptosis, but there is also evidence that antimitotic drugs 
are very effective inhibitors of angiogenesis and may 
thereby additionally act to limit tumor growth (reviewed 
in [26]). The mechanism by which microtubule targeted 
drugs inhibit mitosis and angiogenesis has been thought to 
involve the ability of these agents to suppress microtubule 
dynamics [27]. However, we recently demonstrated that 
low vinblastine and colcemid concentrations that were 
insufficient to inhibit cell division were nonetheless fully 
able to suppress microtubule dynamics, arguing that the 
drugs do not inhibit mitosis simply by suppressing this 
activity [20].  In contrast to the absence of effects on 
mitotic progression, suppression of microtubule dynamics 
had clear effects on cell migration. Subtoxic drug 
concentrations have previously been reported to inhibit 
cell motility [28-30], and our own studies recently showed 
that low, subtoxic concentrations of vinblastine, colcemid, 
and other drugs that affect microtubule assembly are 
able to inhibit cell migration and suppress microtubule 
dynamics  with  similar  dose-response  profiles  [20].  In 
the studies described here, we demonstrated that the 
microtubule stabilizing drug paclitaxel acts in a similar 
manner.
Although there appears to be a close correlation 
between the ability of microtubule targeted drugs to 
suppress microtubule dynamics and their ability to 
inhibit cell migration, there is as yet no direct evidence 
that microtubule dynamics are required for cell motility. 
Previous studies, however, indicated that incorporation 
of  β3-tubulin into microtubules reduced the effect of 
paclitaxel on dynamic instability [21]. If cell migration 
requires that microtubules be dynamic, we reasoned that β3 
expression should also cause cell migration to be relatively 
“resistant” to the effects of the drug. The results described 
here confirmed that hypothesis; the dose responses for 
paclitaxel suppression of microtubule dynamics and 
inhibition of cell migration were both similarly shifted 
to approximately 10-fold higher drug concentrations 
when β3-tubulin was present. This outcome provides the 
strongest evidence to date that dynamic microtubules are 
required for cell motility.
The mechanism by which microtubule dynamics 
affect cell migration is unclear. Cells initiate motility 
by extending a lamellipodium at their leading edge in 
an actin-dependent manner, thereby causing them to 
Figure 6: Calculation of cell movement parameters. 
Microtubule tracks similar to those in Figure 5 were used to 
measure cell velocity (using only intervals during which the 
cells actually moved, solid bars), cell migration (1/2 the rate at 
which the wound closed, open bars), and frequency of pauses 
(number of intervals/h in which there was no cell movement, 
shaded bars).Oncotarget 2011; 2:  368 - 377 374 www.impactjournals.com/oncotarget
stretch in the direction of movement [18]. The trailing 
edge must then release from the substratum and snap 
forward in order for the cell to translocate, and there is 
evidence to suggest that microtubules control this latter 
process  [31].  In  agreement,  we  recently  reported  that 
suppressing microtubule dynamics with vinblastine did 
not stop migrating cells from extending a lamellipodium 
but rather appeared to inhibit the ability of the tail to 
retract [20]. These observations are consistent with the 
discovery that microtubules are stabilized at the leading 
edge of migrating cells but remain dynamic at the trailing 
edge [32]. Microtubule involvement in tail retraction 
could be mediated by effects on adhesion site turnover, 
or by effects on the actin cytoskeleton, but exactly how 
microtubules are involved remains an unsettled question 
[19]. Our data demonstrate that microtubule dynamics are 
critical for their ability to influence cell movement.
Our results also have important clinical implications. 
A number of studies have noted that tumors from diverse 
tissues inappropriately express β3-tubulin, an isoform 
that is normally restricted to brain and Sertoli cells [1, 2]. 
Moreover, β3 is usually seen in tumors that are especially 
difficult to treat and it frequently is found in tumors from 
patients who have relapsed [16, 17, 33]. Again, however, 
these observations represent correlations and there is 
little evidence to suggest that β3 plays a direct role in 
the response to treatment. It is likely that during their 
growth tumor cells have accumulated many mutations 
and other changes that could affect their behavior. Thus, 
the appearance of a protein such as β3 might, or might 
not, have functional consequences. In this regard, it was 
recently shown that β3 is induced in tumors that have 
become hypoxic and/or starved for glucose [34, 35]. 
As such, it might be only one of a series of genes that 
have been activated due to the conditions under which 
the tumor cells are growing, and could be a marker for 
aggressiveness rather than a driver of the behavior.
Arguing in favor of a direct role of β3 in tumor 
cell behavior, a number of studies have reported that 
cells selected for resistance to the cytotoxic effects of 
paclitaxel have increased expression of β3, suggesting 
that this isotype can confer resistance to the drug [13, 
14]. Subsequent studies in our laboratory confirmed this 
idea but demonstrated that increased β3 expression alone 
can only confer very weak 1.5-fold resistance and that it 
acts by altering the extent of microtubule assembly [15]. 
In contrast to the weak effects on the cytotoxic action 
of the drug, we show here that β3 expression produces 
a 10-fold resistance to the ability of paclitaxel to inhibit 
cell migration. Because cell migration is a critical step in 
angiogenesis and tumor cell metastasis, our data suggest 
that β3’s effects on motility are a better explanation for 




Chinese hamster ovary (CHO) cells were grown at 
37 °C and 5% CO2 in α-MEM supplemented with 5% 
fetal  bovine  serum,  50  U/ml  penicillin,  and  50  µg/ml 
streptomycin. HAβ3-5, a CHO cell line that expresses HA-
tagged β3-tubulin under the control of a tetracycline (tet) 
regulated promoter [15], was maintained in the presence 
of tet; β3-tubulin expression was induced by growing the 
cells overnight in medium without tet. Human cancer cell 
lines including HeLa, DU145, MCF7, K562, and KB3 
were grown in α-MEM with 10% fetal bovine serum.
Immunofluorescence
Cells  on  sterile  glass  coverslips  were  fixed  in 
methanol at –20 °C, or in some cases, they were pre-
extracted before fixation by incubating the coverslips for 
1 min at 4 °C in microtubule stabilizing buffer (20 mM 
Tris-HCl (pH 6.8), 1 mM MgCl2, 2 mM EGTA, 0.5% 
NP40) containing 4 µM paclitaxel. Following fixation, the 
cells were rehydrated in PBS and incubated with a 1:100 
dilutions of mouse monoclonal antibody TUJ1 (Covance, 
Princeton, NJ) (to detect β3-tubulin) and rabbit polyclonal 
antibody X2 (gift of Dr. Chloe Bulinski, Columbia 
University) (to detect α-tubulin) for 2 h at 37 °C. The HA 
tagged β3-tubulin overexpressing CHO cells were stained 
with similar dilutions of rabbit polyclonal HA antibody 
(Bethyl Labs, Montgomery, TX) and DM1A (Sigma-
Aldrich, St. Louis, MO), a monoclonal antibody to detect 
α-tubulin. After washing, the cells were further stained for 
1 h with a 1:100 dilutions of Alexa 488-conjugated goat 
anti mouse IgG and Alexa 594-conjugated goat anti rabbit 
IgG (Invitrogen) that included 1 µg/ml 4’,6-diamidino-2-
phenylindole (DAPI) to stain DNA. Cells were viewed 
using an Optiphot microscope (Nikon Inc., Melville, NY) 
equipped with a MagnaFire digital camera (Optronics, 
Goleta, CA).
Electrophoresis and western blots
Cellular proteins were solubilized in SDS sample 
buffer, separated on 7.5% polyacrylamide minigels, and 
transferred to nitrocellulose membranes. The membranes 
were incubated with 1:2,000 dilutions of TUJ1 and actin 
antibody C4 (Chemicon, Temecula, CA) followed by 
Alexa 647-conjugated goat anti-mouse IgG (Invitrogen). 
Bands were detected by fluorescence emission using a 
Storm 860 scanner (GE Healthcare).Oncotarget 2011; 2:  368 - 377 375 www.impactjournals.com/oncotarget
Cell migration assay
Cells were grown in a monolayer to about 85% 
of confluence. A scratch was made at the center of the 
petridish using a wooden toothpick, and fresh medium 
was added with or without paclitaxel. Wound closure was 
monitored using an inverted microscope and 4X phase 
objective. The wound was photographed every 15 minutes 
for 8 h and the rate of wound closure was measured from 
the slope of the gap size plotted against time. This value 
was divided by 2 to arrive at the rate of cell migration at 
each edge of the wound.
 Transwell assay
Approximately 5000 cells were seeded into the 
upper chamber of 24-well cell culture inserts containing 
8 µm membrane pores (BD Biosciences) and allowed to 
settle for 2 h in αMEM containing 10% FBS. Medium 
was then removed and replaced with fresh medium 
containing varying concentrations of paclitaxel. The 
dishes were incubated a further 6 h to allow cell migration, 
and residual cells in the upper chamber were removed 
with a cotton swab. The membranes were then excised, 
fixed  in  methanol,  and  stained  with  DAPI. The  nuclei 
on the bottom membrane surface were counted from 20 
microscopic fields chosen at random using a fluorescence 
microscope and 20X objective. A minimum of 300 cells 
were counted for each data point and the experiment was 
repeated twice.
Transfection and live cell microscopy
Cells were seeded onto sterile 25 mm circular 
coverslips and transfected with EGFP-MAP4 (provided 
by Dr. Joanna Olmsted, University of Rochester) using 
Lipofectamine  (Invitrogen).  After  transfection  the 
cells were maintained in the presence or absence of 
paclitaxel for 2 d and then transferred to McCoy’s 5A 
medium containing 25 mM HEPES (Mediatech) with 
the appropriate concentration of paclitaxel. Images were 
captured 5 s apart at 37 °C using a DeltaVision Core 
imaging system (Applied Precision Inc., Issaquah, WA) 
equipped with a CCD camera and imaging software 
supplied by the vendor. 
Calculating microtubule dynamics
The contour distance between the plus-end of a 
microtubule and an arbitrary reference point on the same 
microtubule  was  measured  using  ImageJ  software  and 
graphed as a function of time to generate life history 
plots. The rates of growth and shortening were calculated 
from the slopes of the plots using linear regression. If the 
change in length of a microtubule between two successive 
time points was greater than 0.5 µm, it was considered 
real growth or shortening; otherwise, it was treated as 
noise.  Catastrophe  was  defined  as  the  transition  from 
either growth or pause to shortening, and the catastrophe 
frequency was calculated as the number of transitions 
divided by the time spent in growth and pause. Rescue 
was defined as the transition from shortening to either 
growth or pause, and the rescue frequency was calculated 
as the number of such events divided by the time spent 
shortening. Dynamicity, an overall measure for how 
dynamic the microtubules behave, was calculated by 
dividing the total change in length (including both growth 
and shortening) of a microtubule by the total time the 
microtubule was under observation. Each parameter was 
calculated from microtubules persisting for more than 2 
min and is expressed as the mean ± standard error. The 
student t-test was used to compare parameters between 
different cell lines and treatments. Differences were 
considered significant when the p value was less than 0.05.
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